Amicus Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Amicus Therapeutics
FOLD Stock  USD 14.36  0.01  0.07%   
Amicus Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Amicus Therapeutics' valuation are provided below:
Gross Profit
561.3 M
Profit Margin
(0.04)
Market Capitalization
4.5 B
Enterprise Value Revenue
7.8284
Revenue
634.2 M
There are over one hundred nineteen available fundamental signals for Amicus Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Amicus Therapeutics' prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 4.6 B. The current year's Enterprise Value is expected to grow to about 4.9 B

Amicus Therapeutics Total Revenue

665.92 Million

Check Amicus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amicus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Interest Expense of 48.5 M or Other Operating Expenses of 629.7 M, as well as many indicators such as Price To Sales Ratio of 6.58, Dividend Yield of 0.0 or PTB Ratio of 16.81. Amicus financial statements analysis is a perfect complement when working with Amicus Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Amicus Stock
Check out the analysis of Amicus Therapeutics Correlation against competitors.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

Amicus Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets494.8 M949.9 M603.2 M
Slightly volatile
Other Assets41.8 M48.6 M54.8 M
Very volatile
Common Stock Shares Outstanding323.8 M308.4 M181.2 M
Slightly volatile
Liabilities And Stockholders Equity517.1 M949.9 M604.5 M
Slightly volatile
Other Stockholder Equity3.2 B3 B1.6 B
Slightly volatile
Total Liabilities709.4 M675.6 M410.7 M
Slightly volatile
Other Current Liabilities210.5 M200.5 M75.9 M
Slightly volatile
Total Current Liabilities249.7 M237.8 M102.8 M
Slightly volatile
Accounts Payable30.1 M28.6 M14.6 M
Slightly volatile
Cash224.7 M214 M124.3 M
Slightly volatile
Short Term Investments143.1 M79.5 M152.8 M
Pretty Stable
Other Current Assets40.4 M38.5 M22.9 M
Slightly volatile
Common Stock3.2 M3 M1.9 M
Slightly volatile
Property Plant Equipment37.2 M35.4 M20.6 M
Slightly volatile
Short and Long Term Debt Total507.5 M483.3 M243.4 M
Slightly volatile
Other Liabilities20.2 M21.3 M75.2 M
Pretty Stable
Property Plant And Equipment Net26.4 M48.2 M30 M
Slightly volatile
Non Current Assets Total214 M273.7 M251.7 M
Slightly volatile
Non Currrent Assets Other8.2 M13.7 M9.6 M
Slightly volatile
Cash And Short Term Investments255.9 M293.5 M271.6 M
Slightly volatile
Common Stock Total Equity3.4 M3.2 M1.9 M
Slightly volatile
Non Current Liabilities Total266.3 M437.8 M299.8 M
Slightly volatile
Property Plant And Equipment Gross84.1 M80.1 M40.9 M
Slightly volatile
Total Current Assets710 M676.2 M378.4 M
Slightly volatile
Short Term Debt6.1 M8.7 M6.9 M
Pretty Stable
Net Receivables121.1 M115.3 M39.6 M
Slightly volatile
Capital Surpluse1.7 B3.1 B1.6 B
Slightly volatile
Non Current Liabilities Other4 M4.2 M87.4 M
Slightly volatile
Warrants71 K74.7 K5.9 M
Pretty Stable
Long Term Debt Total244.7 M450.8 M209.7 M
Slightly volatile
Long Term Investments14 M15.7 M17.2 M
Slightly volatile
Short and Long Term Debt100.3 M189.1 M107.1 M
Slightly volatile
Capital Lease Obligations47.1 M49.7 M29.1 M
Slightly volatile
Net Invested Capital671.5 M666.9 M575.6 M
Slightly volatile
Net Working Capital308.7 M438.3 M355 M
Slightly volatile
Capital Stock3 M3 M2.4 M
Slightly volatile

Amicus Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.9 M7.5 M4.3 M
Slightly volatile
Other Operating Expenses629.7 M599.7 M324.1 M
Slightly volatile
Research Development121.6 M135.8 M144.7 M
Slightly volatile
Total Operating Expenses545.3 M519.3 M300.4 M
Slightly volatile
Selling General Administrative402.7 M383.5 M148.6 M
Slightly volatile
Cost Of Revenue84.4 M80.4 M28.8 M
Slightly volatile
Interest Income5 M3.3 M3.4 M
Slightly volatile
Reconciled Depreciation6.8 M7.5 M5.2 M
Slightly volatile
Extraordinary Items85.5 K90 K1.3 M
Slightly volatile

Amicus Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures4.2 M3.3 M4.6 M
Pretty Stable
End Period Cash Flow228.2 M217.3 M126.1 M
Slightly volatile
Begin Period Cash Flow227.6 M216.7 M115.1 M
Slightly volatile
Depreciation3.8 M2.6 M4 M
Slightly volatile
Stock Based Compensation91.8 M87.4 M40.5 M
Slightly volatile
Change To Netincome61.4 M89.2 M57.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.586.923780.2857
Slightly volatile
Days Sales Outstanding63.0466.3614138
Slightly volatile
Stock Based Compensation To Revenue0.130.13781.9853
Slightly volatile
Capex To Depreciation1.561.28251.5209
Slightly volatile
EV To Sales6.987.348473.3975
Slightly volatile
Inventory Turnover0.330.35130.7401
Slightly volatile
Days Of Inventory On Hand1.1 K1 K910
Slightly volatile
Payables Turnover2.992.80793.3967
Slightly volatile
Sales General And Administrative To Revenue1.191.257.1653
Slightly volatile
Research And Ddevelopement To Revenue0.20.214213.6323
Slightly volatile
Capex To Revenue0.00490.00520.327
Slightly volatile
Cash Per Share0.90.95195.0936
Slightly volatile
Days Payables Outstanding123130850
Pretty Stable
Intangibles To Total Assets0.360.22290.323
Pretty Stable
Current Ratio2.72.84315.0546
Slightly volatile
Receivables Turnover3.655.50024.397
Slightly volatile
Capex Per Share0.01020.01070.4645
Slightly volatile
Revenue Per Share2.162.05670.7838
Slightly volatile
Interest Debt Per Share0.921.71711.1619
Slightly volatile
Debt To Assets0.530.50880.3021
Slightly volatile
Operating Cycle1.2 K1.1 K696
Pretty Stable
Days Of Payables Outstanding123130850
Pretty Stable
Long Term Debt To Capitalization0.640.61260.3722
Slightly volatile
Quick Ratio1.791.8814.829
Slightly volatile
Cash Ratio0.850.89991.582
Slightly volatile
Days Of Inventory Outstanding1.1 K1 K910
Slightly volatile
Days Of Sales Outstanding63.0466.3614138
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.140.90061.0507
Pretty Stable
Fixed Asset Turnover13.813.14535.1205
Slightly volatile
Debt Ratio0.530.50880.3021
Slightly volatile
Price Sales Ratio6.586.923780.2857
Slightly volatile
Asset Turnover0.70.66770.2666
Slightly volatile

Amicus Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.6 B4.4 B2.2 B
Slightly volatile
Enterprise Value4.9 B4.7 B2.3 B
Slightly volatile

Amicus Fundamental Market Drivers

Forward Price Earnings30.4878
Cash And Short Term Investments293.5 M

Amicus Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Amicus Therapeutics Financial Statements

Amicus Therapeutics stakeholders use historical fundamental indicators, such as Amicus Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Amicus Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Amicus Therapeutics' assets and liabilities are reflected in the revenues and expenses on Amicus Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Amicus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue14.3 M9.8 M
Cost Of Revenue80.4 M84.4 M
Total Revenue634.2 M665.9 M
Stock Based Compensation To Revenue 0.14  0.13 
Sales General And Administrative To Revenue 1.25  1.19 
Research And Ddevelopement To Revenue 0.21  0.20 
Revenue Per Share 2.06  2.16 
Ebit Per Revenue 0.05  0.06 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:
How To Invest In Amicus
Details
Is Amicus Stock a good investment?
Details
What is Amicus Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Amicus Therapeutics Correlation against competitors.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Biotechnology sector continue expanding? Could Amicus diversify its offerings? Factors like these will boost the valuation of Amicus Therapeutics. Market participants price Amicus higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Amicus Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
(0.95)
Earnings Share
(0.09)
Revenue Per Share
2.057
Quarterly Revenue Growth
0.237
Return On Assets
0.0249
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Amicus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY